Nordstrom Q2 revenue rises on boost from sales event, shares surge
Donald Trump faces new US indictment in election subversion case
Negotiations so far more effective than rescues in bringing Israeli hostages home from Gaza
Mexico pauses relations with US and Canadian embassies
US says genetically modified wheat safe to grow, pending trials
What to know about the Oropouche virus, also known as sloth fever
Naomi Osaka records first top 10 win in more than four years to reach US Open second round
By Ludwig Burger
FRANKFURT (Reuters) -Bayer said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth prospects for one of the German drugmaker's key pharmaceutical products.
Bayer is developing Nubeqa, also known as darolutamide, jointly with Finland's Orion. The drug is already approved in other prostate cancer treatment settings.
Bayer said in a statement that Nubeqa, when combined with androgen deprivation therapy, significantly prolonged progression-free survival when compared with androgen deprivation therapy alone in a phase III trail.
Trial participants suffered from a type of metastatic prostate cancer that responds to hormone therapy.
Details of the trial would be presented at an as yet undisclosed medical conference, Bayer said, adding that it plans to seek regulatory approval for wider use of the drug.
(Reporting by Ludwig Burger, Editing by Rachel More)
